Reducing alcohol use and improving HIV treatment for men in fishing communities

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This intervention focuses on men living with HIV in fishing communities who engage in hazardous alcohol use. The Kisoboka intervention aims to reduce alcohol consumption and enhance adherence to antiretroviral therapy (ART) through behavioral economics and motivational interviewing techniques. By addressing the unique social and structural challenges in these environments, the study seeks to improve health outcomes and achieve undetectable HIV viral loads. Participants will be screened and referred for support based on their alcohol use and treatment adherence.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. living with HIV;
2. residing in a fishing community (on most days/nights);
3. AUDIT-C positive (≥4) indicating potential hazardous drinking;
4. \>6 months since initial antiretroviral treatment (ART) initiation;
5. not planning to move from the area within the next 6 months;
6. have their own mobile phone and can be reached via phone.
7. an indicator of potential suboptimal treatment as prevention (TasP) either:

(i) last HIV viral load test (within 6 months) was detectable (\>20) or (ii) last viral load test between 6 and 13 months ago was detectable (\>20) and reports missing ≥2 ART doses in the past 2 weeks or (iii) a lack of viral load test results for the prior 13 months in clinic records and reports missing ≥2 ART doses in the past 2 weeks;

Exclusion Criteria:

1. visibly intoxicated at enrollment (eligible to enroll when not intoxicated);
2. does not speak Luganda or English;
3. currently receiving a majority of work payments via mobile money/digital payments;
4. participated in the Kisoboka pilot RCT;
5. unable to read basic Luganda or English

Where it's running

• Makerere University Walter Reed Program affiliated sites in Buikwe, Nakasongola, Mukono, and Kayunga Districts
  Kampala, Uganda Recruiting

Study contacts

• Principal investigator: Susan M Kiene, PhD, MPH — San Diego State University
• Study coordinator: Joseph Matovu, PhD, MHS
• Email: jmatovu@musph.ac.ug
• Phone: +256 414 543872

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Effects of comorbidity on people with severe mental illness

  This study tests how having both alcohol/substance use and a severe mental illness affects hospitalizations, medications, and social participation among adults followed at a mental health center.

  Recruiting Abant Izzet Baysal University · Bolu, Bolu · NCT07692984

• Transcutaneous auricular neurostimulation (tAN) for reducing alcohol withdrawal in people with alcohol use disorder

  This trial will try a five-day ear‑stimulation device (tAN) versus a sham device to reduce alcohol withdrawal symptoms in adults with moderate-to-severe alcohol use disorder.

  Recruiting Spark Biomedical, Inc. · Houston, Texas · NCT07281261

• BrainsWay Deep Transcranial Magnetic Stimulation (Deep TMS) for adults with alcohol use disorder

  This study will test whether BrainsWay Deep TMS can reduce heavy drinking in adults with moderate to severe alcohol use disorder compared with a sham procedure.

  Recruiting at 9 sites Brainsway · Tuscaloosa, Alabama and 10 other locations · NCT07216872

• See if PrEP for WINGS helps with starting and sticking to PrEP among women in community supervision programs

  This study tests PrEP for WINGS plus PrEP compared with PrEP alone to see if it increases PrEP initiation and adherence among cisgender women in CSPs who use alcohol hazardously and may face IPV and HIV risk.

  Recruiting Columbia University · New York, New York · NCT06853314

• Functional connectivity–guided transcranial magnetic stimulation for alcohol use disorder

  This study will test whether a single fMRI-guided session of transcranial magnetic stimulation (TMS) can reduce alcohol-cue brain reactivity and help people with moderate-to-severe alcohol use disorder stay abstinent.

  Recruiting VA Palo Alto Health Care System · Palo Alto, California · NCT06415721

• Psilocybin versus ketamine for reducing heavy drinking in alcohol use disorder

  This trial will test whether a single 30 mg dose of psilocybin or a weight-based 0.75 mg/kg dose of ketamine, each given with individual psychotherapy, can reduce heavy drinking in adults with moderate to severe alcohol use disorder.

  Recruiting Phase 2 University of Iowa · Iowa City, Iowa · NCT06405607

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.